On pharmacogenetic approaches to hypertension treatment in pregnant women

1. Клинические рекомендации. Артериальная гипертония у беременных. М.; 2016. Доступно по: https://medi.ru/klinicheskie-rekomendatsii/arterialnaya-gipertoniya-u-beremennykh_13865 [Clinical recommendations. Arterial hypertension in pregnant women. Moscow; 2016. Available at: https://medi.ru/klinicheskie-rekomendatsii/arterialnaya-gipertoniya-u-beremennykh_13865(in Russian)].
2. Манухин И.Б., Маркова Е.В., Маркова Л.И., Стрюк Р.И. Комбинированная низкодозовая антигипертензивная терапия у беременных с артериальной гипертонией и гестозом. Кардиология. 2012; 52(1): 32–8. [Manukhin I.B., Markova E.V., Markova L.I., Stryuk R.I. Combined low-dose antihypertensive therapy in pregnant women with hypertension and preeclampsia. Cardiology/Kardiologiya. 2012; 52(1): 32–8. (in Russian)].
3. Nabhan A.F., Elsedawy M.M. Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension. Cochrane Database Syst. Rev. 2011; (7): CD006907. https://dx.doi.org/10.1002/14651858.CD006907.pub2.
4. Magee L.A., Pels A., Helewa M., Rey E., von Dadelszen P.; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. Obstet. Gynaecol. Can. 2014; 36(5): 416–41. https://dx.doi.org/10.1016/s1701-2163(15)30588-0.
5. Диагностика и лечение сердечно-сосудистых заболеваний при беременности. Российские рекомендации. Российский кардиологический журнал. 2013; 18(4, Приложение 1): 1–40. [Diagnosis and treatment of cardiovascular disease in pregnancy. Russian recommendations. Russian Cardiology Journal/Rossiiskii kardiologicheskii zhurnal. 2013; 18(4, Suppl. 1): 1–40. (in Russian)].
6. Luizon M.R., Palei A.C., Cavalli R.C., Sandrim V.C. Pharmacogenetics in the treatment of preeclampsia: current findings, challenges and perspectives. Pharmacogenomics. 2017; 18(6): 571–83. https://dx.doi.org/10.2217/pgs-2016-0198.
7. Blobel B. Translational medicine meets new technologies for enabling personalized care. Stud. Health Technol. Inform. 2013; 189: 8–23. PMID: 23739350
8. Минздрав Российской Федерации. Стратегия развития медицинской науки в Российской Федерации до 2025 года. М.; 2018. Доступно по: https://www.rosminzdrav.ru/documents/5413-rasporyazhenie-pravitelstva-rossiyskoy-federatsii-ot-28-de [Minzdrav Russian. Strategy for the development of medical science in the Russian Federation until 2025. Moscow; 2018. Available at: https://www.rosminzdrav.ru/documents/5413-rasporyazhenie-pravitelstva-rossiyskoy-federatsii-ot-28-de (in Russian)].
9. Johnson J.A., Cavallari L.H. Pharmacogenetics and cardiovascular disease implications for personalized medicine. Pharmacol. Rev. 2013; 65(3): 987–1009. https://dx.doi.org/10.1124/pr.112.007252.
10. Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. Клиническая фармакогенетика. Кукес В.Г., Бочков Н.П., ред. М.: ГЭОТАР-Медиа; 2007. [Sychev D.A., Ramenskaya G.V., Ignat’ev I.V., Kukes V.G. Clinical pharmacogenetics. Kukes V.G., Bochkov NP., eds. Moscow: GEOTAR-Media; 2007. (in Russian)].
11. Кукес В.Г., Сычев Д.А., Аль-Ахмед Фейсал, Дмитриев В.А. Влияние индивидуальных особенностей пациентов на риск развития нежелательных лекарственных реакций. Вестник Росздравнадзора. 2011; 6: 59–63. [Kukes V.G., Sychev D.A., Al’-Akhmed Feisal, Dmitriev V.A.Influence of individual characteristics of patients on the risk of unwanted drug reactions. Vestnik Roszdravnadzora. 2011; (6): 59–63. (in Russian)].
12. Сторожаков Г.И., Федотова Н.М., Верещагина Г.С., Червякова Ю.Б. Эндотелиальная дисфункция при артериальной гипертензии. Лечебное дело. 2005; 4: 58–64. [Storozhakov G.I., Fedotova N.M., Vereshchagina G.S., Chervyakova Yu.B. Endothelial dysfunction in arterial hypertension. Medical Case/ Lechebnoe delo. 2005; (4): 58–64. (in Russian)].
13. Крестова Н.Е., Арилешере А.Е., Волобуев А.И., Азлина Н.В. К вопросу о диагностике плацентарной недостаточности у больных с приобретенными пороками сердца. Акушерство и гинекология. 1990; 2: 22–6. [Krestova N.E., Arileshere A.E., Volobuev A.I., Azlina N.V. On the diagnosis of placental insufficiency in patients with acquired heart defects. Obstrectis and Gynecology/Akusherstvo i ginekologiya. 1990; (2): 22–6. (in Russian)].
14. Ванина Л.В. Беременность и сердечно-сосудистая патология. М.: Медицина; 1991. [Vanina L.V. Pregnancy and cardiovascular pathology.Moscow: Meditsina; 1991. (in Russian)].
15. Куба А.А., Никонова Ю.М., Феликсова О.М., Хромова А.В., Бебякова Н.А. Ассоциация генетического полиморфизма гена эндотелиальной синтазы оксида азота с сердечно-сосудистой патологии. Современные проблемы науки и образования. 2015; 3: 19. [Kuba A.A., Nikonova Yu.M., Feliksova O.M., Khromova A.V., Bebyakova N.A. Association of the polymorphism of endothelial nitric oxide synthase and cardiovascular diseases. Modern Problems of Science and Education/Sovremennye problemy nauki i obrazovaniya. 2015; (3): 19.(in Russian)].
16. Бебякова Н.А., Хромова А.В., Феликсова О.М. Взаимосвязь периферической вазоконстрикции с полиморфизмом т-786с гена эндотелиальной синтазы оксида азота. Медицинские науки. 2013; 12(2): 176–9. [Bebyakova N.A., Khromova A.V., Feliksova O.M. Interrelation of peripheral vasoconstriction with polymorphism of t-786c gene of endothelial nitric oxide synthase. Medical Sciences/Medicinskie nauki. 2013; 12(2): 176–9.(in Russian)].
17. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 1997; 100(9): 2153–7.
18. Щёкотова А.П., Кривцов А.В., Булатова И.А., Загородских Е.Б. Эндотелиальная дисфункция и полиморфизм гена эндотелиальной синтазы оксида азота (nos3) при хронических заболеваниях печени. Современные проблемы науки и образования. 2012; 2: 109. [Schekotova A.P., Krivtsov A.V., Bulatova I.A., Zagorodskikh E.B. Endothelial dysfunction and polymorphism of endothelial nitric oxide synthase (nos3) gene in chronic hepatic diseases. Modern Problems of Science and Education/Sovremennye problemy nauki i obrazovaniya. 2012; (2): 109. (in Russian)].
19. Casas J.P., Bautista L.E., Humphries S.E., Hingorani A.D. Endothelial nitric oxide synthase genotype and ischemic disease. Meta-analysis of 26 studies involving 23028 subjects. Circulation. 2004; 109(11): 1359–65. https://dx.doi.org/10.1161/01.CIR.0000121357.76910.A3.
20. Hingorani A.D., Jia H., Stevens P. A common variant in exon 7 of the endothelial constitutive nitric oxide synthase gene. Clin. Sci. 1995; 88: 21. doi: 10.1161/01.cir.100.14.1515
21. Asakimori Y., Yorioka N., Taniguchi Y., Ito T., Ogata S., Kyuden Y., Kohno N. T(-786)–>C polymorphism of the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron. 2002; 91(4): 747–51. https://dx.doi.org/10.1159/000065041.
22. Wang X.L., Sim A.S., Badenhop R.F., McCre-die R.M., Wilcken D.E. A smoking dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat. Med. 1996; 2(1): 41–5.
23. Зотова И.В., Затейщиков Д.А., Сидоренко Б.А. Синтез оксида азота и развитие атеросклероза. Кардиология. 2002; 42(4): 58–67. [Zotova I.V., Zateishchikov D.A., Sidorenko B.A. Synthesis of nitric oxide and the development of atherosclerosis. Cardiology/ Kardiologiya. 2002; 42(4): 58–67. (in Russian)].
24. Глотов О.С., Глотов А.С., Тарасенко О.А., Иващенко Т.Э., Баранов В.С. Исследование функционально-значимого полиморфизма ACE, AGTR1,eNOS, MTHFR, MTRR и APOE генов в популяции Северо-Западного региона России. Экологическая генетика. 2004; 2(3): 32–5. [Glotov O.S., Glotov A.S., Tarasenko O.A., Ivashchenko T.E., Baranov V.S. Study of the functionally significant polymorphism of ACE, AGTR1, eNOS, MTHFR, MTRR and APOE genes in the population of the North-West region of Russia. Ecological Genetics/Ekologicheskaya genetika. 2004; 2(3): 32–5.(in Russian)].
25. Мозговая Е.В. Исследование генетической предрасположенности к гестозу: полиморфизм генов, участвующих в регуляции функции эндотелия. Журнал акушерства и женских болезней. 2003; 52(2): 25–34. [Mozgovaya E.V. Investigation of genetic predisposition to gestosis: polymorphism of genes involved in the regulation of endothelial function. Journal of Obstetrics and Women’s Diseases/Zhurnal akusherstva i zhenskikh boleznei. 2003; 52(2):25–34. (in Russian)].
26. Салов И.А. Дисфункция эндотелия как один из патогенетических факторов расстройств микроциркуляции при гестозе. Российский вестник акушера-гинеколога. 2006; 6(6): 4-9. [Salov I.A. Endothelial dysfunction as one of the pathogenetic factors of microcirculatory disorders in gestosis. The Russian Bulletin of the Obstetrician-Gynecologist/Rossiiskii vestnik akushera-ginekologa. 2006; 6(6): 4–9. (in Russian)].
27. Воронько О.Е., Чистяков Д.А., Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш., Носиков В.В., Дебабов В.Г., Дедов И.И. Полиморфизм гена эндотелиальной NO-синтазы и генетическая предрасположенность к нефропатии при инсулинзависимом сахарном диабете. Сахарный диабет. 1999; 2: 2–3. [Voron’ko O.E., Chistyakov D.A., Shestakova M.V., CHugunova L.A., Chugunova L.A., Shamkhalova M.Sh., Nosikov V.V., Debabov V.G., Dedov I.I. Polymorphism of endothelial NO synthase gene and genetic predisposition to nephropathy in insulin-dependent diabetes mellitus. Diabetes/Sakharnyi diabet. 1999; (2): 2–3.(in Russian)].
28. Tesauro M., Thompson W.C., Rogliani P., Qi L., Chaudhary P.P., Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary disease: cleavage of proteins with aspartate vs. position 298. Proc. Natl. Acad. Sci. USA. 2000; 97(6): 2832–5. https://dx.doi.org/10.1073/pnas.97.6.2832.
29. Khalkhali-Ellis Z., Hendrix M.J. Nitric oxide regulation of maspin expression in normal mammaty epithelial and breast cancer cells. Am. J. Pathol. 2003; 162(5): 1411–7. https://dx.doi.org/10.1016/S0002-9440(10)64274-5.
30. Тепляков А.Т., Шилов С.Н., Березикова Е.Н. Яковлева Н.Ф., Маянская С.Д., Попова А.А., Лукша Е.Б., Воронина Е.Н., Торим Ю.Ю., Карпов Р.С. Полиморфизм генов eNOS и iNOS при хронической сердечной недостаточности у больных ишемической болезнью сердца. Кардиология. 2010; 4: 45–7. [Teplyakov A.T., Shilov S.N., Berezikova E.N., Yakovleva N.F., Mayanskaya S.D., Popova A.A., Luksha E.B., Voronina E.N., Torim Yu.Yu., Karpov R.S. Polymorphism of eNOS and iNOS genes in chronic heart failure in patients with ischemic heart disease. Cardiology/Kardiologiya. 2010; (4): 45–7. (in Russian)].
31. Nakayama M., Yasue H., Yoshimura M., Shimasaki Y., Kugiyama K., Ogawa H. et al. T-786C mutation in the 5’-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999; 99(22): 2864–70.
32. Sandrim V.C., Palei A.C., Cavalli R.C., Araújo F.M., Ramos E.S., Duarte G., Tanus-Santos J.E. eNOS haplotypes associated with gestational hypertension or pre-eclampsia. Pharmacogenomics. 2008; 9(10): 1467–73. https://dx.doi.org/10.2217/14622416.9.10.1467.
33. Sandrim V.C., Palei A.C., Sertorio J.T., Cavalli R.C., Duarte G., Tanus-Santos J.E. Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. Mol. Hum. Reprod. 2010; 16(7): 506–10. https://dx.doi.org/10.1093/molehr/gaq030.
34. Guo S. Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms. J. Endocrinol. 2014; 220(2): T1-23. https://dx.doi.org/10.1530/JOE-13-0327.
35. Polyakova J., Zavodovsky B., Seewordova L., Akhverdyan Y., Zborovskaya I.. Pathogenic relationship between osteoarthritis, overweight and inflammation. Ann. Rheum. Dis. 2015;74(Suppl. 2): 372. https://dx.doi.org/10.1136/annrheumdis-2015-eular.1129.
36. Zhang L.Q., Heruth D.P., Shui Qing Ye. Nicotinamide phosphoribosyltransferase in human diseases. J. Bioanal. Biomed. 2011; 3: 13-25. https://dx.doi.org/10.4172/1948-593X.1000038.
37. Garten A., Petzold S., Körner A., Imai S., Kiess W. Nampt: linking NAD biology, metabolism, and cancer. Trends Endocrinol. Metab. 2009; 20(3): 130–8. https://dx.doi.org/10.1016/j.tem.2008.10.004.
38. Revollo J.R., Körner A., Mills K.F., Satoh A., Wang T., Garten A. et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007; 6(5): 363–75. https://dx.doi.org/10.1016/j.cmet.2007.09.003.
39. Moschen A.R., Geiger S., Gerner R., Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat. Res. 2010; 690(1–2): 95–101. https://dx.doi.org/10.1016/j.mrfmmm.2009.06.012.
40. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 2002; 32(11): 3225–34. https://dx.doi.org/10.1002/1521–4141(200211)32:11<3225.
41. Ognjanovic S., Bao S., Yamamoto S.Y., Garibay-Tupas J., Samal B., Bryant-Greenwood G.D. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 2001; 26(2): 107–17.
42. Curat C.A., Wegner V., Sengenès C., Miranville A., Tonus C., Busse R., Bouloumié A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006; 49(4):744–7. https://dx.doi.org/10.1007/s00125-006-0173-z.
43. Luizon M.R., Belo V.A., Palei A.C., Amaral L.M., Lacchini R., Sandrim V.C. et al. Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/ NAMPT levels in hypertensive disorders of pregnancy. Hypertens. Res. 2015; 38(5): 361–6. https://dx.doi.org/10.1038/hr.2015.15.
44. Коваль С.Н., Снегурская И.А., Мысниченко О.В. Семейство васкулоэндотелиального фактора роста и его возможная роль в патогенезе артериальных гипертензий. Семейство васкулоэндотелиального фактора роста и его возможная роль в патогенезе артериальных гипертензий. Артериальная гипертензия. 2012; 4: 85–91. [Koval’ S.N., Snegurskaya I.A., Mysnichenko O.V. The family of vasculoendothelial growth factor and its possible role in the pathogenesis of arterial hypertension. Arterial Hypertension/ Arterial’naya gipertenziya. 2012; (4): 36–41.(in Russian)].
45. Luizon M.R., Palei A.C.T., Belo V.A., Amaral L.M., Lacchini R., Duarte G. et al. Gene–gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 2017; 17(5): 427–34. https://dx.doi.org/10.1038/tpj.2016.35.
46. Luizon M.R., Palei A.C., Sandrim V.C., Amaral L.M., Machado J.S., Lacchini R. et al. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J.. 2014; 14(6): 535–41. https://dx.doi.org/10.1038/tpj.2014.26.
47. Palei A.C., Sandrim V.C., Amaral L.M., Machado J.S., Cavalli R.C., Lacchini R. et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 2012; 12(6): 489–98. https://dx.doi.org/10.1038/tpj.2011.31.
48. Palei A.C., Sandrim V.C., Amaral L.M., Machado J.S., Cavalli R.C., Lacchini R. et al. Effects of matrix metalloproteinase (MMP)-2 polymorphisms on responsiveness to antihypertensive therapy of women with hypertensive disorders of pregnancy. Basic Clin. Pharmacol. Toxicol. 2012; 111(4): 262–7. https://dx.doi.org/10.1111/j.1742-7843.2012.00905.x.
49. Sandrim V.C., Palei A.C., Eleuterio N., Tanus-Santos J.E., Cavalli R.C. Antihypertensive therapy in pre-eclampsia is not modulated by VEGF polymorphisms. Arch. Gynecol. Obstet. 2015; 291(4): 799–803. https://dx.doi.org/10.1007/s00404-014-3475-2.
50. Sandrim V.C., Palei A.C., Luizon M.R., Izidoro-Toledo T.C., Cavalli R.C., Tanus-Santos J.E. eNOS haplotypes affect the responsiveness to antihypertensive therapy in pre-eclampsia but not in gestational hypertension. Pharmacogenomics J. 2010; 10(1): 40–5. https://dx.doi.org/10.1038/tpj.2009.38.

Received 01.10.2019

Accepted 04.10.2019